Uncommon low-grade brain tumors

Thankamma Ajithkumar; Naduni Imbulgoda; Elliott Rees; Fiona Harris; Gail Horan; Amos Burke; Sarah Jefferies; Stephen Price; Justin Cross; Kieren Allinson

doi:10.1093/neuonc/noy151

Uncommon low-grade brain tumors

Thankamma Ajithkumar^*, Naduni Imbulgoda, Elliott Rees, Fiona Harris, Gail Horan, Amos Burke, Sarah Jefferies, Stephen Price, Justin Cross, Kieren Allinson

^*Corresponding author for this work

Cancer and Genomic Sciences

Research output: Contribution to journal › Article › peer-review

Abstract

The 2016 World Health Organization (WHO) classification of primary central nervous system (CNS) tumors includes numerous uncommon (representing ≤1% of tumors) low-grade (grades I-II) brain neoplasms with varying clinical behaviors and outcomes. Generally, gross tumor or maximal safe resection is the primary treatment. Adjuvant treatments, though their exact role is unknown, may be considered individually based on pathological subtypes and a proper assessment of risks and benefits. Targetable mutations such as BRAF (proto-oncogene B-Raf), TRAIL (tumor necrosis factor apoptosis inducing ligand), and PDGFR (platelet derived growth factor receptor) have promising roles in future management.

Original language	English
Pages (from-to)	151-166
Number of pages	16
Journal	Neuro-Oncology
Volume	21
Issue number	2
DOIs	https://doi.org/10.1093/neuonc/noy151
Publication status	Published - 14 Feb 2019

Bibliographical note

Publisher Copyright:
© 2018 The Author(s).

Keywords

brain tumors
low-grade
mutations
treatment

ASJC Scopus subject areas

Oncology
Clinical Neurology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/neuonc/noy151

Cite this

@article{e5eba6f0b3cd47d4baf236855790be47,

title = "Uncommon low-grade brain tumors",

abstract = "The 2016 World Health Organization (WHO) classification of primary central nervous system (CNS) tumors includes numerous uncommon (representing ≤1% of tumors) low-grade (grades I-II) brain neoplasms with varying clinical behaviors and outcomes. Generally, gross tumor or maximal safe resection is the primary treatment. Adjuvant treatments, though their exact role is unknown, may be considered individually based on pathological subtypes and a proper assessment of risks and benefits. Targetable mutations such as BRAF (proto-oncogene B-Raf), TRAIL (tumor necrosis factor apoptosis inducing ligand), and PDGFR (platelet derived growth factor receptor) have promising roles in future management.",

keywords = "brain tumors, low-grade, mutations, treatment",

author = "Thankamma Ajithkumar and Naduni Imbulgoda and Elliott Rees and Fiona Harris and Gail Horan and Amos Burke and Sarah Jefferies and Stephen Price and Justin Cross and Kieren Allinson",

note = "Publisher Copyright: {\textcopyright} 2018 The Author(s).",

year = "2019",

month = feb,

day = "14",

doi = "10.1093/neuonc/noy151",

language = "English",

volume = "21",

pages = "151--166",

journal = "Neuro-Oncology",

issn = "1522-8517",

publisher = "Oxford University Press",

number = "2",

}

TY - JOUR

T1 - Uncommon low-grade brain tumors

AU - Ajithkumar, Thankamma

AU - Imbulgoda, Naduni

AU - Rees, Elliott

AU - Harris, Fiona

AU - Horan, Gail

AU - Burke, Amos

AU - Jefferies, Sarah

AU - Price, Stephen

AU - Cross, Justin

AU - Allinson, Kieren

PY - 2019/2/14

Y1 - 2019/2/14

N2 - The 2016 World Health Organization (WHO) classification of primary central nervous system (CNS) tumors includes numerous uncommon (representing ≤1% of tumors) low-grade (grades I-II) brain neoplasms with varying clinical behaviors and outcomes. Generally, gross tumor or maximal safe resection is the primary treatment. Adjuvant treatments, though their exact role is unknown, may be considered individually based on pathological subtypes and a proper assessment of risks and benefits. Targetable mutations such as BRAF (proto-oncogene B-Raf), TRAIL (tumor necrosis factor apoptosis inducing ligand), and PDGFR (platelet derived growth factor receptor) have promising roles in future management.

AB - The 2016 World Health Organization (WHO) classification of primary central nervous system (CNS) tumors includes numerous uncommon (representing ≤1% of tumors) low-grade (grades I-II) brain neoplasms with varying clinical behaviors and outcomes. Generally, gross tumor or maximal safe resection is the primary treatment. Adjuvant treatments, though their exact role is unknown, may be considered individually based on pathological subtypes and a proper assessment of risks and benefits. Targetable mutations such as BRAF (proto-oncogene B-Raf), TRAIL (tumor necrosis factor apoptosis inducing ligand), and PDGFR (platelet derived growth factor receptor) have promising roles in future management.

KW - brain tumors

KW - low-grade

KW - mutations

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85057605501&partnerID=8YFLogxK

U2 - 10.1093/neuonc/noy151

DO - 10.1093/neuonc/noy151

M3 - Article

C2 - 30239861

AN - SCOPUS:85057605501

SN - 1522-8517

VL - 21

SP - 151

EP - 166

JO - Neuro-Oncology

JF - Neuro-Oncology

IS - 2

ER -

Uncommon low-grade brain tumors

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Fingerprint

Cite this